Compounding group sues FDA for removing Lilly’s weight loss drug from shortage list

FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego

(Reuters) – A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs from its shortage list last week, a move expected to curtail compounding facilities’ ability to sell their own versions of the drugs.

In a lawsuit in Fort Worth, Texas federal court, the Outsourcing Facilities Association claims the FDA removed tirzepatide from the list even though it remains in short supply. Lilly sells the drug under the brand names Zepbound for weight loss and Mounjaro for diabetes.

(Reporting By Brendan Pierson in New York; Editing by Chris Reese)